Retatrutide Trial Investigates Heart and Kidney Benefits in Obese Adults

Obesity is a global health crisis, significantly increasing the risk of severe comorbidities like Atherosclerotic Cardiovascular Disease (ASCVD), a condition where plaque builds up in arteries, and Chronic Kidney Disease (CKD), a progressive loss of kidney function. While new anti-obesity medications show promise, their direct impact on long-term cardiovascular and kidney outcomes in high-risk populations remains a critical area of research. This study aims to determine if the novel triple-agonist Retatrutide can reduce major adverse cardiovascular and kidney events in adults with obesity and pre-existing ASCVD or CKD.

As an active, not-yet-recruiting study, there are no findings to report yet. However, the primary purpose is to investigate if Retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The study aims to assess the effect of Retatrutide on major adverse cardiovascular events (MACE), which include cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. It also seeks to evaluate its impact on major adverse kidney events, such as sustained eGFR (estimated glomerular filtration rate) decline or end-stage kidney disease. The main objective is to determine if Retatrutide can significantly reduce the combined incidence of major adverse cardiovascular events and major adverse kidney events in this high-risk population. Secondary objectives will likely include changes in body weight, blood pressure, and other metabolic markers.